# Achilles Therapeutics plc (ACHL)

Source: https://www.quantisnow.com/company/ACHL
Generated: 2026-11-13T20:24:36.008Z

- Ticker: ACHL
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Biological Products (No Diagnostic Substances)
- IPO year: 2021
- Website: https://www.achillestx.com

## About

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. It is also developing products for use in the treatment of head and neck squamous cell carcinoma, renal cell carcinoma, triple negative breast cancer, and bladder cancer. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. The company was founded in 2016 and is headquartered in London, the United Kingdom.

## Latest ACHL news and filings

- 2025-03-21 13:41 UTC [SEC Form 15-12G filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-achilles-therapeutics-plc-5955548)
- 2025-03-20 21:30 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5954924)
- 2025-03-19 20:16 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-achilles-therapeutics-plc-5952382)
- 2025-03-19 20:13 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-achilles-therapeutics-plc-5952317)
- 2025-03-19 20:11 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-achilles-therapeutics-plc-5952288)
- 2025-03-19 20:09 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-achilles-therapeutics-plc-5952263)
- 2025-03-12 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-effect-filed-by-achilles-therapeutics-plc-5939686)
- 2025-03-11 11:15 UTC [SEC Form POS AM filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-achilles-therapeutics-plc-5937259)
- 2025-03-11 11:00 UTC [SEC Form 25 filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-25-filed-by-achilles-therapeutics-plc-5937208)
- 2025-02-28 13:16 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5916356)
- 2025-02-28 12:00 UTC [Achilles Therapeutics Announces Voluntary Nasdaq Delisting and SEC Deregistration](https://www.quantisnow.com/insight/achilles-therapeutics-announces-voluntary-nasdaq-delisting-and-sec-deregistration-5916132)
- 2025-02-13 22:02 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-achilles-therapeutics-plc-5888206)
- 2025-02-11 17:48 UTC [SEC Form 144] [SEC Form 144 filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-achilles-therapeutics-plc-5881556)
- 2025-02-06 17:55 UTC [SEC Form 144] [SEC Form 144 filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-achilles-therapeutics-plc-5875167)
- 2025-02-06 17:50 UTC [SEC Form 144] [SEC Form 144 filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-achilles-therapeutics-plc-5875164)
- 2025-02-06 17:39 UTC [SEC Form 144] [SEC Form 144 filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-achilles-therapeutics-plc-5875160)
- 2025-02-06 12:15 UTC [SEC Form 144] [SEC Form 144 filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-144-filed-by-achilles-therapeutics-plc-5874565)
- 2025-02-04 11:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5868627)
- 2025-01-06 21:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5834747)
- 2024-12-26 12:22 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5824693)
- 2024-12-24 14:30 UTC [Achilles Therapeutics Announces Sale of Technology Assets to AstraZeneca](https://www.quantisnow.com/insight/achilles-therapeutics-announces-sale-of-technology-assets-to-astrazeneca-5824576)
- 2024-12-02 13:28 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5795326)
- 2024-11-19 12:00 UTC [Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market](https://www.quantisnow.com/insight/achilles-therapeutics-receives-approval-to-transfer-to-nasdaq-capital-market-5781780)
- 2024-11-14 21:23 UTC [SEC Schedule 13G] [Amendment: SEC Form SC 13G/A filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/amendment-sec-form-sc-13ga-filed-by-achilles-therapeutics-plc-5776197)
- 2024-11-14 14:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5773771)
- 2024-11-14 12:00 UTC [Earnings] [Achilles Therapeutics Reports Third Quarter 2024 Financial Results](https://www.quantisnow.com/insight/achilles-therapeutics-reports-third-quarter-2024-financial-results-5773052)
- 2024-09-25 23:14 UTC [SEC Schedule 13G] [SEC Form SC 13G filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-sc-13g-filed-by-achilles-therapeutics-plc-5705091)
- 2024-09-19 11:17 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5698986)
- 2024-09-19 11:00 UTC [Achilles Therapeutics Announces Strategic Update](https://www.quantisnow.com/insight/achilles-therapeutics-announces-strategic-update-5698935)
- 2024-08-14 12:04 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5658306)
- 2024-08-14 11:00 UTC [Earnings] [Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates](https://www.quantisnow.com/insight/achilles-therapeutics-reports-second-quarter-2024-financial-results-and-recent-5658068)
- 2024-08-05 20:06 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5642180)
- 2024-06-27 20:05 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5581361)
- 2024-05-24 11:00 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5515268)
- 2024-05-22 11:07 UTC [Market Chatter] [Achilles Therapeutics And Arcturus Therapeutics Announce Research Collaboration To Explore mRNA Cancer Vaccines](https://www.quantisnow.com/insight/achilles-therapeutics-and-arcturus-therapeutics-announce-research-collaboration-to-explore-5508977)
- 2024-05-22 11:00 UTC [Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines](https://www.quantisnow.com/insight/achilles-therapeutics-announces-research-collaboration-with-arcturus-therapeutics-to-explore-5508907)
- 2024-05-17 21:15 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5501560)
- 2024-05-17 21:00 UTC [Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement](https://www.quantisnow.com/insight/achilles-therapeutics-receives-nasdaq-deficiency-notice-regarding-minimum-bid-price-5501348)
- 2024-05-08 11:44 UTC [SEC Form 6-K] [SEC Form 6-K filed by Achilles Therapeutics plc](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-achilles-therapeutics-plc-5469983)
- 2024-05-08 11:00 UTC [Earnings] [Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights](https://www.quantisnow.com/insight/achilles-therapeutics-reports-first-quarter-2024-financial-results-and-recent-5469579)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ACHL
- Earnings history: https://www.quantisnow.com/earnings/ACHL
- Dividend history: https://www.quantisnow.com/dividends/ACHL
- Insider transactions: https://www.quantisnow.com/insiders/ACHL
- Options chain: https://www.quantisnow.com/options/ACHL
- SEC 8-K filings only: https://www.quantisnow.com/company/ACHL/8-k
- RSS and alerts for ACHL: https://www.quantisnow.com/docs/rss-feeds.md